HAEMATO : distributes PCR point-of-care devices

Schönefeld, 13^th January 2022 - With the current omicron wave, laboratories in Germany are facing a sharp increase in PCR testing. The evaluation capacities are pushing increasingly towards their limits, especially with regards to the new quarantine regulations.

HAEMATO PHARM GmbH ("HAEMATO"), a 100% subsidiary of HAEMATO AG (ISIN: DE000289VV1), has now added a high-end PCR point-of-care device to its portfolio. This device can perform a reliable RT(real-time)-PCR analysis within 45 minutes. HAEMATO already supplies numerous pharmacies, clinics and laboratories, thus reducing the workload of these facilities.

RT-PCR testing is the so-called gold standard among corona tests. The polymerase chain reaction (PCR) can be used to reliably detect pathogens in a sample from the respiratory tract mucous membranes. As the RT-PCR devices offered by HAEMATO can be used on site (point-of-care), the long way from taking the sample to the analysing laboratory is saved. The entire process is thus considerably shortened and thus accelerated.

"In addition to our day-to-day business of supplying medicines, we are currently working non-stop to supply pharmacies, clinics, laboratories and public institutions with RT-PCR devices, rapid antigen tests and FFP2 masks," says Patrick Brenske, CEO of HAEMATO AG. Attila Strauss, Managing Director of HAEMATO PHARM GmbH added: "We recognised the potential overload in healthcare at an early stage and with the addition of the PCR Point-of-Care devices to our product portfolio, we are now in a position to make an important contribution to the battle against the Corona pandemic."

The PCR Point-of-Care devices as well as standard rapid antigen tests and FFP2 masks are available for order and immediate delivery via the website www.schnelltest-antigen.de.